Active Biotech's partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-AC...
October 19 2017 - 08:00AM
Lund, October 19,
2017 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces
that the collaboration partner Teva Pharmaceutical Industries Ltd.
(NYSE and TASE: TEVA) will present new data on laquinimod, an
investigational MS therapy in three presentations at the
7th Joint
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment
and Research in Multiple Sclerosis (ACTRIMS) in Paris, October
25-28, 2017. For further information, please see
www.tevapharm.com.
Teva-sponsored data on laquinimod include:
[P1.431] Transcriptomic Analysis
of Disease Reversal in EAE: Comparison of Laquinimod and
FTY-720 (Poster Session 1, October 26, 2017, 3:30 - 5:00 p.m.)
H. Belinson, S. Barash, J. Kaye, E. Raymond, D.
Laifenfeld, R. Laufer
[P13.233] CONCERTO: A
Placebo-Controlled Trial of Oral Laquinimod in Patients With
Relapsing-Remitting Multiple Sclerosis (Oral Presentation,
Parallel Session 13 - Update on relapsing-remitting MS management,
October 27, 2017, 3:04 - 3:16 p.m.) G. Comi, T.L.
Vollmer, A. Boyko, P. Vermersch, T. Ziemssen, X. Montalban, F.D.
Lublin, N. Sasson, Y. Dadon, J.R. Steinerman, V.
Knappertz
[EP1778] Laquinimod
Regulates Inflammatory Gene Induction in a Human Model of Reactive
Astrogliosis (ePosters will be displayed for the duration of
the congress; however, they will not be presented during specific
sessions) C. Chapouly, J. Mariani, J. Zhang, N.
Zach, G.R. John
About
laquinimod
Laquinimod is a once-daily oral, investigational, selective aryl
hydrocarbon receptor (AhR) activator targeting neurodegeneration
and inflammation with a novel mechanism of action being developed
for the treatment of relapsing-remitting MS (RRMS),
primary-progressive MS (PPMS) and Huntington disease
(HD).
Lund October 19, 2017
Active Biotech AB (publ)
For further information, please
contact:
Helén Tuvesson, President & CEO
Tel +46 46 19 20 95
Email: helen.tuvesson@activebiotech.com
Hans Kolam, CFO
Tel +46 46 19 20 44
Email: hans.kolam@activebiotech.com
Active Biotech AB (publ)
(Nasdaq Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in Phase 2 development for the treatment of primary
progressive multiple sclerosis and Huntington's disease. Anyara,
cancer immunotherapy, previously in clinical Phase 1-2/3
development in patients with pancreatic-, lung- or renal cancer.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
The information was submitted for publication
at 14.00 a.m. CET on November
19, 2017.
Teva presents new data on laq for
the treatment of MS at ECTRIMS
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2023 to Mar 2024